Public release date: 14-Aug-1998
[
| E-mail
|
Share
]
Contact: Klaus Scheffzek
Klaus.Scheffzek@mpi-dortmund.mpg.de
Fax: 49-231-1206-23
Max-Planck-Gesellschaft
Team Of Max Planck Scientists Elucidates Structure Of A Protein Segment Involved In 'Von Recklinghausen Neurofibromatosis'
Ribbon diagram of a hypothetical complex between Ras and NF1-GAP. The figure was generated by
superimposing the structural model of NF1-GAP with that of the complex between Ras and the GAP segment of
p120GAP, to give a realistic albeit hypothetical impression of how NF1-GAP interacts with Ras. Regions of Ras
important for the interactions are highlighted in turquoise, those of NF1 in light blue. The large domain of
NF1-GAP is in blue, the small one in yellow. Segments that are presumably mobile in the protein are in red, shown
in conformations that are derived from those of the corresponding regions in p120GAP. The position of the
functionally most important residues are highlighted as balls in magenta on NF1-GAP and in green on Ras.
Positions of mutations found in NF1 patients are highlighted as white balls.
Full size image available through contact
|
Scientists at the Max Planck Institute for
Molecular Physiology in Dortmund and of the Max Planck
Institute for Medical Research in Heidelberg (Germany) have
determined the first structure of a functional protein unit
that is involved in the development of von
Recklinghausen neurofibromatosis. This unit is a
regulator of another protein involved in the pathogenesis of
numerous tumors, linking neurofibromatosis to tumor
development. The work, published in the August 3, 1998, issue
of EMBO Journal, confirms
mechanistic ideas about the function of this protein stemming
from the authors' fundamental structural and biochemical
studies of the related protein p120GAP (Mittal et al., 1996, Science 273, 115-117;
Scheffzek et al., 1996, Nature
384, 591-596; Scheffzek et al., 1997, Science 277, 333-338;
Ahmadian et al., 1997, Nature
Struct. Biol. 4, 686-689).
von Recklinghausen neurofibromatosis, also called type 1
neurofibromatosis or simply NF1, is an inherited disease that
predisposes the formation of certain types of tumors and may
be associated with a number of other symptoms including
learning disabilities and mental retardation. So-called Lish
nodules of the iris or pigmentation abnormalities of the skin
(so-called café-au-lait spots) and
neurofibromas, benign cutaneous tumors, are hallmarks of NF1
with important diagnostic relevance. In rare cases, NF1 may
develop into malignant tumors.
The so-called NF1 gene is responsible for the development of
the disease. It codes a huge protein, termed neurofibromin,
comprising nearly 3000 amino acids, and it is disrupted or
mutated in patients affected with NF1. A segment comprising
ca. 10% of the whole protein represents the only known
functional module of neurofibromin. It functions as a
negative regulator of Ras, another protein that is intimately
involved in the regulation of cell growth and
differentiation. The physiological importance of this is
underscored by the observation that Ras carries
characteristic mutations in 30% of all cancer tumors.
Ras can be thought of as a binary signal switch cycling
between ON and OFF states which are characterized in terms of
a small molecule, a guanine nucleotide, bound to the protein.
In the resting cell, Ras is tightly bound to guanosine
diphosphate (GDP), which is exchanged for guanosine
triphosphate (GTP) upon binding of extracellular stimuli to
cell membrane receptors. In the GTP-bound form, Ras interacts
specifically with so-called effector proteins, thereby
initiating cascades of protein-protein interactions that may
finally lead to cell proliferation. To return to the inactive
OFF state, Ras cleaves off the terminal phosphate moiety, the
g -phosphate, of GTP in an
enzymatic process, the intrinsic GTPase reaction. The
remaining GDP-bound Ras is no longer able to interact with
effectors, it is switched OFF. The process of GTP cleavage is
very slow: Ras splits one GTP every 30 minutes. But upon
interaction with neurofibromin, the rate is enhanced 100,000
fold: the underlying process is termed GTPase activation,
making neurofibromin a GTPase activating protein (GAP). A
common feature of the Ras mutations found in tumors is the
inability of the resulting Ras proteins to cleave GTP
efficiently, i.e. to turn off the switch; in addition they
are not sensitive to GTPase activation by neurofibromin.
Thus, understanding neurofibromin function also means
understanding aspects of Ras function, linking NF1 to
cancerogenesis.
Apart from neurofibromin, there are other GTPase activating
proteins specific for Ras; in living organisms, it is indeed
common that identical processes are carried out by different
components. The first GAP to be discovered was the p120GAP
(Trahey & McCormick, 1987, Science 238, 542-545).
In fundamental studies involving biochemical and structural
methods, the research team has previously included p120GAP to
elucidate the molecular mechanism behind the GTPase
activation process. p120GAP, represented by the segment of
the protein that is sufficient to stimulate Ras-mediated GTP
hydrolysis, complements the active site which is where the
reaction takes place. It does so by two strategies: Firstly,
it supplies an amino acid (an arginine) that participates
directly in the reaction; its mutation to another amino acid
destroys GAP activity. Secondly, it stabilizes the
functionally most important amino acids on Ras, thereby
aligning the catalytic machinery (Scheffzek et al., Science 277, 333-338).
The structure of neurofibromin GAP resembles the structure of
the corresponding segment of p120GAP: it is an elongated
molecule that is composed of a small and a large domain, the
latter of which contains all the functionally important
residues. Together with the biochemical analyses, the
structural similarity confirms that it functions by the same
mechanism. On the basis of the structural work on
neurofibromin and p120GAP complexed with Ras, the effect of
mutations in the GAP segment, as found in NF1-patients, can
be analyzed; e.g. the catalytic arginine contributed by GAP
has been found mutated in an NF1 patient; the resulting GAP
protein has an intact structure but is completely inactive
(Klose et al., 1998, Hum. Mol. Genet. 7, 1261-1268). Since
this mutation was the only one found in the whole NF1 gene of
the respective patient, it appears that loss of GAP function
is sufficient for the development of neurofibromatosis.
The medical impact of the work on neurofibromin and p120GAP is twofold: on the one hand it is now possible to
picture how neurofibromin acts on Ras and to analyze mutations in the light of the structure; on the other hand, the
structure of the contact area between GAP and Ras suggests that it might be attractive to search for small molecules
that may act as surrogate GAPs in tumor cells where Ras is fatally mutated or its GTP-bound levels are increased for
other reasons, e.g. due to a missing neurofibromin function. The 3-dimensional picture of GAP and of its
communication with Ras may suggest how to proceed, but also indicates us that it will be an extremely formidable
task.
###
[
| E-mail
|
Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.